Share This Article:

Resveratrol Reverses the Impaired Vasodilation Observed in 2K-1C Hypertension through Endothelial Function Improvement

Abstract Full-Text HTML Download Download as PDF (Size:463KB) PP. 61-69
DOI: 10.4236/ojmc.2014.42004    4,237 Downloads   5,147 Views  


Background: The production of endothelial-derived factors induces either vasoconstriction or vasodilation; nitric oxide (NO) is the most distinguished relaxing factor. Endothelial dysfunction is associated with hypertension. The partial loss in the NO-promoted vasodilation is due to its decreased bioavailability and/or to an activity reduction of endothelium NO synthase (eNOS). Reactive oxygen species (ROS), present in oxidative stress, seize NO and diminish its bioavailability. Transresveratrol (RESV) has been proved to increase NO and eNOS levels. Thus, RESV could be capable of improving NO dependent vascular relaxation on aortic rings isolated from treated 2K-1C animals through ROS damage reduction. Aim: Evaluate the effects of RESV treatment on the relaxation of aortic rings isolated from treated 2K-1C rats while focusing on the effects of the treatment on systolic blood pressure. Methods: Male Wistar rats (180 g) were grouped: two 2K-1C and two Sham groups, one of each was treated with RESV (20 mg/kg, gavage) dissolved in Tween 80 and one of each was treated with water plus Tween 80 (control) for six weeks. The rats had their systolic blood pressure (SBP) measured before and after the treatments. Vascular reactivity studies were conducted in order to observe and compare acetylcholine (ACh)-induced relaxations in the presence and absence of the NOS inhibitor L-NAME (10-4 mol/L). Results: SBP for 2K-1C was significantly reduced in the treated group (179.13 ± 4.90 mmHg, n = 23) when compared to the untreated group (196.66 ± 6.06 mmHg, n = 15, p < 0.01). The maximum relaxation of aortic rings isolated from the 2K-1C treated group showed a higher efficacy (116.63% ± 1.72%, n = 12) than that from the untreated group (85.97% ± 0.69%, n = 6, p < 0.001); L-NAME exposure was responsible for a significant decrease in each group’s maximum relaxation efficacy. Conclusions: SBP reduction observed after RESV treatment in rat renal hypertension could be due to the reestablishment of vascular relaxation depend of NO.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Pereira, B. , Scalabrini, A. , Marinho, T. , Antonietto, C. and Restini, C. (2014) Resveratrol Reverses the Impaired Vasodilation Observed in 2K-1C Hypertension through Endothelial Function Improvement. Open Journal of Medicinal Chemistry, 4, 61-69. doi: 10.4236/ojmc.2014.42004.


[1] Lim, S.S., et al. (2012) A Comparative Risk Assessment of Burden of Disease and Injury Attributable to 67 Risk Factors and Risk Factor Clusters in 21 Regions, 1990-2010: A Systematic Analysis for the Global Burden of Disease Study 2010. Lancet, 380, 2224-2260.
[2] World Health Organization (2009) WHO/UNICEF Estimates of National Immunization Coverage. World Health Organization, Geneva.
[3] Kannel, W.B. (1996) Blood Pressure as a Cardiovascular Risk Factor: Prevention and Treatment. The Journal of the American Medical Association, 273, 1571-1576.
[4] Dórea, E.L. and Lotufo, P.A. (2004) Epidemiologia da Hipertensao Arterial Sistêmica. Revista da Sociedade Brasileira de Hipertensao, 7, 86-93.
[5] Santos, J.C., Faria Jr., M. and Restini, C.B.A. (2012) Potenciais interacoes medicamentosas identificadas em prescricoes a pacientes hipertensos. Rev Bras Clin Med., 10, 1-10.
[6] Hashmi, S.K., Afridi, M.B., Abbas, K., Sajwani, R.A., Saleheen, D., et al. (2007) Factors Associated with Adherence to Anti-Hypertensive Treatment in Pakistan. PLoS ONE, 2, 1-8.
[7] American College of Preventive Medicine (2011) Medication Adherence Time Tool: Improving Health Outcomes.
[8] Sarquis, L.M.M., et al. (1998) A Adesao ao Tratamento na Hipertensao Arterial: Analise da Producao Científica. Revista da Escola de Enfermagem da USP, 32, 353-355.
[9] Clark, L.T., et al. (1991) Improving Compliance and Increasing Control of Hypertension: Needs of Special Hypertensive Populations. American Heart Journal, 121, 664-669.
[10] Jin, J., Sklar, G.E., Oh, V.M.S. and Li, S.C. (2008) Factors Affecting Therapeutic Compliance: A Review from the Patient’s Perspective. Therapeutics and Clinical Risk Management, 4, 269-286.
[11] Furchgott, R. and Zawadzki, J.V.B. (1980) The Obligatory Role of Endothelial Cells in The Relaxation of Arterial Smooth Muscle by Acetylcholine. Nature, 288, 373-376.
[12] Verma, S. and Anderson, T.J. (2002) Fundamentals of Endothelial Function for the Clinical Cardiologist. Circulation, 105, 546-549.
[13] Moncada, S. and Higgs, A. (2012) The L-Arginine-Nitric Oxide Pathway. The New England Journal of Medicine, 1993, 329.
[14] Dzau, V.J. (1989) Significance of Endothelial Derived Vasoactive Substances. Journal of Vascular Medicine and Biology, I, 43-55.
[15] Endemann, D. and Schiffrin, E. (2004) Endothelial Dysfunction. Frontiers in Nephrology, 15, 1983-1992.
[16] Sotomayor, M.A., Perez-Guerrero, C., Herrera, M.D. and Marhuenda, E. (1999) Effects of Chronic Treatment with Simvastatin on Endothelial Dysfunction in Spontaneously Hypertensive Rats. Journal of Hypertension, 17, 769-776.
[17] Calver, A., Collier, J., Moncada, S. and Vallance, P. (1992) Effect of Local Intra-Arterial NG-Monomethil-L-Arginine in Patients with Hypertension: The Nitric Oxide Dilator Mechanism Appears Abnormal. Journal of Hypertension, 10, 1025-1031.
[18] Schiffrin, E.L. (2001) A Critical Review of the Role of Endothelial Factors in the Pathogenesis of Hypertension. Journal of Cardiovascular Pharmacology, 38, S3-S6.
[19] Koppenol, W.H., Moreno, J.J., Pryor, W., Ischiropoulos, H. and Beckman, J.S. (1992) Peroxynitrite, a Cloaked Oxidant Formed by Nitric Oxide and Superoxide. Chemical Research in Toxicology, 5, 834-842.
[20] Milstien, S. and Katusic, Z. (1999) Oxidation of Tetrahydrobiopterin by Peroxynitrite: Implications for Vascular Endothelial Function. Biochemical and Biophysical Research Communications, 263, 681-684.
[21] Landmesser, U. and Harrison, D.G. (2001) Oxidative Stress and Vascular Damage in Hypertension. Coronary Artery Disease, 12, 455-461.
[22] Grossman, E. (2008) Does Increased Oxidative Stress Cause Hypertension? Diabetes Care, 31, S185-S189.
[23] Han, X.Z., Shen, T. and Lou, H.X. (2007) Dietary Polyphenols and Their Biological Significance. International Journal of Molecular Sciences, 8, 950-988.
[24] Wang, S.J., Wang, X.X., Yan, J., Xie, X.D., Fan, F.H., Zhou, X.H., Han, L. and Chen, J.Z. (2007) Resveratrol Inhibits Proliferation of Cultured Rat Cardiac Fibroblasts: Correlated With NO-cGMP Signaling Pathway. European Journal of Pharmacology, 567, 26-35.
[25] Goldblatt, H., Lynch, J., Hamzal, R. and Summerville, W.W. (1934) Studies on Experimental Hypertension, I: The Production of Persistent Elevation of Systolic Blood Pressure by Means of Renal Ischemia. Journal of Experimental Medicine, 59, 347-379.
[26] Mok, J., Kong, M. and Hutchinson, J. (1985) Cardiovascular Effects of Central and Peripheral Administration of Dopamine in Hypertensive and Normotensive Rats. Indian Journal of Pharmacology, 17, 192-196.
[27] Boulanger, C. and Lüscher, T.F. (1990) Release of Endothelin from the Porcine Aorta: Inhibition by Endothelium-Derived Nitric Oxide. Journal of Clinical Investigation, 85, 587-590.
[28] Fazan, J.R.R., Silva, V.J.D. and Salgado, H.C. (2001) Modelos De Hipertensao Arterial. Revista Brasileira De Hipertensao, 8, 19-29.
[29] Simone, G., Devereux, R.B., Chinali, M., Roman, M.J., Best, L.G., Welty, T.K., Lee, E.T., Howard, B.V. for the Strong Heart Study Investigators (2006) Risk Factors for Arterial Hypertension in Adults with Initial Optimal Blood Pressure: The Strong Heart Study. Hypertension, 47, 162-167.
[30] Usui, M., Egashira, K., Kitamoto, S., Koyanagi, M., Katoh, M., Kataoka, C., Shimokawa, H. and Takeshita, A. (1999) Pathogenic Role of Oxidative Stress in Vascular Angiotensin-Converting Enzyme Activation in Long-Term Blockade of Nitric Oxide Synthesis in Rats. Hypertension, 34, 546-551.
[31] Callera, G.E., Varanda, W.A. and Bendhack, L.M. (2000) Impaired Relaxation to Acetylcholine in 2K-1C Hypertensive Rat Aortas Involves Changes in Membrane Hyperpolarization Instead of an Abnormal Contribution of Endothelial Factors. General Pharmacology, 34, 379-389.
[32] Callera, G.E., Varanda, W.A. and Bendhack, L.M. (2001) Ca2+ Influx Is Increased in 2-Kidney, 1-Clip Hypertensive Rat Aorta. Hypertension, 38, 592-596.
[33] Lunardi, C.N., da Silva, R.S. and Bendhack, L.M. (2009) New Nitric Oxide Donors Based on Ruthenium Complexes. Brazilian Journal of Medical and Biological Research, 42, 87-93.
[34] Callera, G.E., Varanda, W.A. and Bendhack, L.M. (2000) Impaired Relaxation to Acetylcholine in 2K-1C Hypertensive Rat Aortas Involves Changes in Membrane Hyperpolarization Instead of an Abnormal Contribution of Endothelial Factors. General Pharmacology, 34, 379-389.
[35] Mantelli, L., Amerini, S. and Ledda, F. (1995) Roles of Nitric Oxide and Endothelium-Derived Hyperpolarizing Factor in Vasorelaxant Effect of Acetylcholine as Influenced by Aging and Hypertension. Journal of Cardiovascular Pharmacology, 25, 595-602.
[36] Heitzer, T., Wenzel, U., Hink, U., Krollner, D., Skatchkov, M., Stahl, R.A.K., Macharzina, R., Brasen, J.H., Meinertz, T. and Münze, T. (1999) Increased NAD(P)H Oxidase-Mediated Superoxide Production in Renovascular Hypertension: Evidence for an Involvement of Protein Kinase C. Kidney International, 55, 252-260.
[37] Okamura, T., Miyazaki, M., Inagami, T. and Toda, N. (1986) Vascular Renin-Angiotensin System in Two Kidney, One Clip Hypertensive Rats. Hypertension, 8, 560-565.
[38] Martinez-Maldonado, M. (1991) Pathophysiology of Renovascular Hypertension. Hypertension, 17, 707-719.
[39] Guan, S., Fox, J., Mitchell, K.D. and Navar, L.G. (1992) Angiotensin and Angiotensin Converting Enzyme Tissue Levels in Two-Kidney, One Clip Hypertensive Rats. Hypertension, 20, 763-767.
[40] Kojda, G. and Harrison, D. (1999) Interactions between NO and Reactive Oxygen Species: Pathophysiological Importance in Atherosclerosis, Hypertension, Diabetes and Heart Failure. Cardiovascular Research, 43, 562-571.
[41] Rubany, G.M. and Vanhoutte, P.M. (1986) Superoxide Anions and Hyperoxia Inactivate Endothelium-Derived Relaxing Factor. American Journal of Physiology, 250, H822-H827.
[42] Dell'agli, M., Busciala, A. and Bosisio, E. (2004) Vascular Effects of Wine Polyphenols. Cardiovascular Research, 63, 593-602.
[43] de Oliveira, J.C., Antonietto, C.R.K., Scalabrini, A.C., Marinho, T.S., Pernomian, L. and Corrêa, J.W.N. (2012) Antioxidant Protective Effects of the Resveratrol on the Cardiac and Vascular Tissues from Renal Hypertensive Rats. Open Journal of Medicinal Chemistry, 2, 61-71.
[44] Sobey, C.G. (2001) Potassium Channel Function in Vascular Disease. Arteriosclerosis, Thrombosis and Vascular Bio- logy, 21, 28-38.
[45] Lima, M.S., de Souza Veras Silani, I., Toaldo, I.M., Corrêa, L.C., Telles Biasoto, A.C., Pereira, G.E., Bordignon-Luiz, M.T. and Ninow, J.L. (2014) Phenolic Compounds, Organic Acids and Antioxidant Activity of Grape Juices Produced from New Brazilian Varieties Planted in the Northeast Region of Brazil. Food Chemistry, 161, 94-103.
[46] Dolinsky, V., Chakrabarti, S., Pereira, T.J., Oka, T., Levasseur, J., Beker, D., Zordoky, B.N., Morton, J.S., Nagendran, J., Lopaschuk, G.D., Davidge, S.T. and Dyck, J.R.B. (2013) Resveratrol Prevents Hypertension and Cardiac Hypertrophy in Hypertensive Rats and Mice. Biochimica et Biophysica Acta, 1832, 1723-1733.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.